HSBC Holdings plc Cuts Hikma Pharmaceuticals Plc (HIK) Price Target to GBX 865

Hikma Pharmaceuticals Plc (LON:HIK) had its target price reduced by HSBC Holdings plc from GBX 1,060 ($13.94) to GBX 865 ($11.38) in a research note released on Friday. HSBC Holdings plc currently has a reduce rating on the stock.

Other equities research analysts also recently issued reports about the stock. Numis Securities Ltd reissued an add rating and set a GBX 1,560 ($20.52) price target on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, August 17th. Morgan Stanley cut shares of Hikma Pharmaceuticals Plc to an equal weight rating and decreased their price objective for the company from GBX 1,600 ($21.04) to GBX 1,350 ($17.76) in a report on Monday, August 21st. Stifel Nicolaus cut shares of Hikma Pharmaceuticals Plc to a hold rating and reduced their price target for the company from GBX 2,300 ($30.25) to GBX 1,320 ($17.36) in a report on Tuesday, August 29th. Peel Hunt reiterated a hold rating and issued a GBX 1,390 ($18.28) price target on shares of Hikma Pharmaceuticals Plc in a report on Tuesday, October 31st. Finally, Jefferies Group LLC reduced their price target on shares of Hikma Pharmaceuticals Plc from GBX 1,390 ($18.28) to GBX 1,045 ($13.74) and set a hold rating for the company in a report on Monday, August 21st. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company’s stock. Hikma Pharmaceuticals Plc currently has a consensus rating of Hold and an average target price of GBX 1,321.91 ($17.39).

Hikma Pharmaceuticals Plc (HIK) opened at GBX 950 ($12.50) on Friday. Hikma Pharmaceuticals Plc has a 12 month low of GBX 934 ($12.28) and a 12 month high of GBX 2,346 ($30.86).

WARNING: This piece of content was originally published by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://baseballnewssource.com/markets/hsbc-holdings-plc-cuts-hikma-pharmaceuticals-plc-hik-price-target-to-gbx-865/1774551.html.

Hikma Pharmaceuticals Plc Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.